GlassScriptPhysician profile
Paul Alappat
NPI 1801970645
$5,725.54
in general payments reported to CMS, 2019-2025
33 companies · $339 in 2025
The $339 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,287 · 2020: $1,273 · 2021: $717 · 2022: $237 · 2023: $416 · 2024: $455 · 2025: $339.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,191 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,191.09 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $820.30 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $657.13 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $613.16 | 2019-2024 | Wainua, Farxiga |
| Amgen INC. | $443.00 | 2019-2023 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $425.68 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $334.51 | 2019-2025 | Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $272.22 | 2019-2025 | Lifevest |
| Boston Scientific Corporation | $244.94 | 2019-2022 | |
| Novo Nordisk INC | $222.91 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $216.65 | 2019-2024 | |
| Amarin Pharma, INC. | $187.33 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $138.14 | 2019-2023 | Verquvo |
| Gilead Sciences, INC. | $122.70 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $116.74 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $113.41 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $103.66 | 2019-2021 | |
| Lilly USA, LLC | $100.64 | 2019-2021 | |
| Lantheus Medical Imaging, INC. | $96.85 | 2021-2024 | |
| Edwards Lifesciences Corporation | $83.55 | 2020 | |
| Lundbeck LLC | $71.81 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $67.15 | 2019-2021 | |
| Philips North America LLC | $43.43 | 2020-2023 | |
| Abbott Laboratories | $35.17 | 2024 | Amplatzer Amulet |
| Scpharmaceuticals INC. | $34.02 | 2023 | |
| Akcea Therapeutics, INC. | $27.11 | 2019 | |
| Esperion Therapeutics, INC. | $21.57 | 2025 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.18 | 2024 | Xifaxan |
| Astellas Pharma US INC | $17.69 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $16.96 | 2023 | Inpefa |
| Vifor Pharma, INC. | $16.76 | 2021 | |
| Pfizer INC. | $13.57 | 2022 | |
| Currax Pharmaceuticals LLC | $13.49 | 2021 | |
| Allergan, INC. | $12.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Alappat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.